Review: Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression

Home/Review: Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression

Review: Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression

Review: Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression

This observational study found that half of the patient with negative IgM and RT-qPCR-positive SARS-CoV-2 had severe COVID-19 disease. 

  • IgM-based gold immunochromatographic assay (GICA) is the test used within this study, to investigate its utility
  • Severe cases were defined as patients requiring ICU level care and receiving treatment for 3 days.
  • The IgM-GICA positivity from the RT-qPCR confirmed COVID-19 patients is shown to be 82.2% (37/45)
  • Specificity testing of IgM-GICA did not detect SARS-CoV-2 antibodies in human sera infected with other viruses or from healthy people
  • IgM detection rates were substantially lower in patients who progressed to severe disease as opposed to mild disease:
  • At 4–7 days after symptom onset, the positive rate of the mild group was 64% (16/25), compared to 16.7% (1/6) in the severe group
  • At 15–21 days after symptom onset, the positive rate of the mild group was 100% (15/15), compared to 75% (6/8) in the severe group
|2020-06-03T11:07:16-04:00June 3rd, 2020|COVID-19 Literature|0 Comments

About the Author: Megan McHenry

Megan McHenry
Megan S. McHenry, MD, MS, FAAP is a pediatrician and an Assistant Professor of Pediatrics in the Ryan White Center for Pediatric Infectious Disease and Global Health at Indiana University School of Medicine. Dr. McHenry's research focuses on early childhood development in children living in resource-limited settings. This work is frequently aligned with community-engaged research and dissemination and implementation science frameworks. She primarily conducts research in collaboration with the Academic Model for Providing Access to Healthcare (AMPATH) Research Network in Kenya. Dr. McHenry currently has a career development award through the National Institutes of Health to develop a neurodevelopmental screening program for children born to HIV-infected mothers in Kenya. Dr. McHenry is also the Director of Pediatric Global Health Education and a co-Director of the Morris Green Physician-Scientist Development Program at Indiana University School of Medicine. In additional to global health lectures, she also educates residents and students on early childhood development, basic biostatistical techniques, research methodologies, and research ethics. She mentors multiple pediatric fellows, residents, and medical students interested in early childhood development within global contexts.

Get Involved with Indiana CTSI